Dexamethasone Sodium Phosphate Injection, USP, 100 mg/ 10 mL, (10 mg/mL), 10x10 mL Multiple Dose Vials, Rx only, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873, NDC carton: 70069-025-10; NDC vial: 70069-025-01
Published March 25, 2026 · Recall initiated: February 4, 2026
Summary
FDA records drug Class II recall D-0398-2026, published March 25, 2026 and initiated February 4, 2026. Recalling firm: SOMERSET THERAPEUTICS LLC; Status: Ongoing; Reported quantity: 62190 vials; Lot: Lot #: A240421, Exp 07/31/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Impurities/Degradation Specifications - OOS impurities result observed during long term stability testing at product expiry (24 months) were above specs for these impurities: Dexamethasone Sodium Phosphate EP impurity G (Impurity RU 49336) and dexamethasone formate.
What to do
Voluntary: Firm initiated · Letter
Get an email if DEXAMETHASONE SODIUM PHOSPHATE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- DEXAMETHASONE SODIUM PHOSPHATE
- Manufacturer
- SOMERSET THERAPEUTICS LLC
- Distributor
- Nationwide in the USA
- UPC
- 0370069025109
- Lot
- Lot #: A240421, Exp 07/31/2026
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAPitavastatin Tablets, 2 mg, packaged in 90-count bottles, Rx only, Manufactured for: Northstar Rx LLC,March 25, 2026
- FDABrimonidine Tartrate/Timolol Maleate Ophthalmic Solution 0.2%/0.5%*, 5 mL, Rx Only, Sterile, Apotex Corp.March 25, 2026
- FDAChildren's Ibuprofen Oral Suspension, USP, 100 mg per 5mL, 4 FL OZ (120 mL) bottle, Manufactured for: TaroMarch 25, 2026
- FDADexamethasone Sodium Phosphate injection USP, 120mg per 30mL (4mg/mL), 30 mL Multiple-Dose Vial, Rx only,June 26, 2024
- FDADexamethasone Sodium Phosphate Injection, USP, 4 mg/mL, 1 mL Vials (NDC 0641-6145-01), packaged in 25 x 1 mLNovember 29, 2017
- FDADexamethasone Sodium Phosphate Injection, USP, 20 mg/5 mL (4 mg/mL), 5 mL Vials (NDC 0641-6146-01), packagedNovember 29, 2017
Questions about this recall
Was Dexamethasone Sodium Phosphate Injection, USP, 100 mg/ 10 mL, (10 mg/mL), 10x10 mL Multiple Dose Vials, Rx only, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873, NDC carton: 70069-025-10; NDC vial: 70069-025-01 recalled?
Yes. FDA published recall D-0398-2026 on March 25, 2026. Reported hazard: Failed Impurities/Degradation Specifications - OOS impurities result observed during long term stability testing at product expiry (24 months) were above specs for these impurities: Dexamethasone Sodium Phosphate EP impurity G (Impurity RU 49336) and dexamethasone formate.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: DEXAMETHASONE SODIUM PHOSPHATE. UPC: 0370069025109.